Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (“Know Labs” or the “Company”) (OTC: KNWN), an emerging leader in non-invasive medical diagnostics, announced it completed and closed its most recent financing with an aggregate total of $5,739,500. The aggregate total includes a closing on April 25, 2020 of $2,632,500 and a closing on May 26, 2020, of the Company’s final round of a convertible debt offering with gross proceeds of $3,107,000 in exchange for issuing Subordinated Convertible Notes (the “Convertible Notes”) and Warrants (the “Warrants”) in a private placement with accredited investors. The Convertible Notes will be automatically and mandatorily converted to Common Stock at the lower of $1.00 per share on the one year anniversary or at a 25% discount to a Qualified Financing. The most recent Convertible Notes have a principal amount of $3,107,000 and bear annual interest of 8%. Both the principal amount and the interest are payable on a payment-in-kind basis in shares of Common Stock of the Company (the “Common Stock”). The Warrants were granted on a 1:0.5 basis (one-half Warrant for each full share of Common Stock into which the Convertible Notes are convertible). The Warrants have a five-year term and an exercise price equal to 120% of the per share conversion price of the Qualified Financing or other mandatory conversion. The Convertible Notes are initially convertible into 3,107,000 shares of Common Stock, subject to certain adjustments, and the Warrants are initially exercisable for 1,553,500 shares of Common Stock at an exercise price of $1.20 per share of Common Stock, also subject to certain adjustments.
Know Labs aims to create non-invasive biosensors capable of detecting and measuring biomolecules continuously. This has applications for a new area of personal health and medicine that may allow issues derived from abnormal blood glucose, hormone, medications, and metabolite levels to be discovered in real time. Know Labs has a foundational IP portfolio of 14 issued and 24 pending patents with an aggressive IP development plan in place. In early April, Know Labs was granted a patent on its Bio-RFID™ technology, entitled “Health Related Diagnostics Employing Spectroscopy in Radio/Microwave Frequency Band.” Know Labs’ first focus with its Bio-RFID™ technology is the wearable non-invasive continuous monitoring of blood glucose levels, an important breakthrough for the diabetes community. The Company is making progress engineering the UBAND Continuous Glucose Monitor (CGM) into its market ready form for clinical trials later this year, the results of which will be submitted to the US Food and Drug Administration for approval. Know Labs plans to initially enter the diabetic Continuous Glucose Monitoring (CGM) market with its UBAND non-invasive CGM product; and to later enter other clinical monitoring markets for continuous, non-invasive hormone, metabolite, and biomolecular monitoring, and the Company believes that each of these applications could potentially translate into very significant market opportunities. The Company’s announcement can be found here: www.sec.gov/Archives/edgar/data/1074828/000116169720000166/form_8-k.htm
Contact Pete Conley for more information: Managing Director Head of Intellectual Property (IP) Banking 310-383-7874 email@example.com
Click here to learn more about this offering
This press release is not a solicitation or offer to buy or sell securities. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved. Clinical trials are in early stages.
About Know Labs, Inc. Know Labs, Inc. (OTC: KNWN) is a technology company that is developing and commercializing a completely new class of clinical non-invasive biosensors potentially capable of detecting and measuring – continuously and in real-time – biomolecules such as blood glucose, hormone levels, medications, and metabolites – to potentially usher in a new era of personal health and personalized medicine. Know labs has a foundational IP portfolio of 14 issued and 24 pending patents with an aggressive IP development plan in place. The executive team is comprised of technology inventors, technology/healthcare executives, and product developers responsible for leading Know Labs from a developmental-stage company to commercialization and scale. For more information, please visit www.knowlabs.co. About Boustead Securities, LLC Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com. About Sutter Securities Group, Inc. Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC, and Sutter Securities Incorporated, FINRA member broker-dealers; Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. Sutter Securities Group, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws. SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.flashfunders.com. Forward-Looking Statements This announcement contains forward-looking statements. Forward-looking statements provide our current expectations or forecasts of future events. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements in this announcement include, but are not limited to, statements regarding our disclosure concerning the Company’s operations, cash flows, financial position and dividend policy.